JacquelineCBarrientosMDMS

Hematology • Miami Beach, FL

Hematologic Oncology

Adjunct Professor, Medicine, Zucker School of Medicine

Join to view full profile

Dr. Barrientos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Barrientos' full profile

Already have an account?

Office
4306 Alton Rd 3rd floor
Miami Beach, FL 33140
Phone+1 305-535-3300

Education & Training

New York Presbyterian Hospital (Cornell Campus)Fellowship, Hematology and Medical Oncology, 2006 - 2009
Yale-New Haven Medical CenterResidency, Internal Medicine, 2002 - 2005
Ponce Health Sciences University School of MedicineClass of 2001

Certifications & Licensure

FL State Medical License 2022 - 2026
NY State Medical License 2006 - 2023
CT State Medical License 2005 - 2012

Clinical Trials

A Phase I Study of GNKG168 in Patient With Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia (B-CLL) Start of enrollment: 2009 Sep 01
Terminated
Phase 1
Study of the Bruton's Tyrosine Kinase Inhibitor in Subjects With Relapsed/Refractory Marginal Zone Lymphoma Start of enrollment: 2013 Dec 01
Completed
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Study of Ibrutinib & Obinutuzumab With/Without CHOP for Richter's Transformation or Richter's Syndrome Patients Start of enrollment: 2017 Jun 19
Terminated
Phase 2
Join now to see all

Publications & Presentations

PubMed

874 citations
Resistance Mechanisms for the Bruton's Tyrosine Kinase Inhibitor Ibrutinib
Jennifer A. Woyach, Richard R. Furman, Ta-Ming Liu, Hatice Gulcin Ozer, Marc Zapatka
The New England Journal of Medicine. 2014-06-11
1216 citations
Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
Michael L. Wang, Simon Rule, Peter Martin, Andre Goy, Rebecca Auer
The New England Journal of Medicine. 2013-08-07
114 citations
Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial.
Tait D Shanafelt, Xin Victoria Wang, Curtis A Hanson, Elisabeth M Paietta, Susan O'Brien
Blood. 2022-07-14

Abstracts/Posters

Acalabrutinib Monotherapy in Patients with Relapsed/Refractory Chronic Lymphocytic Leukemia: 42-Month Follow-up of a Phase 2 Study
Jacqueline C. Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
CLL B Cells Develop Resistance to Ibrutinib By Reinvigorating the IL-4R - IL-4 Axis Blocked By BrutonÍs Tyrosine Kinase Inhibitors Including Acalabrutinib and Zanubrut...
Jacqueline C Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Jacqueline C. Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Efficacy of Therapies Following Venetoclax Discontinuation in CLL: Focus on B-Cell Receptor Signal Transduction Inhibitors and Cellular Therapies
Jacqueline C Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E19...
Jacqueline C. Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Cirmtuzumab, a ROR1 Targeted Mab, Reverses Cancer Stemness, and Its Combination with Ibrutinib Is Safe and Effective: Planned Analysis of the Cirll Phase 1/2 Trial for...
Jacqueline C. Barrientos, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Join now to see all

Lectures

Defined Duration Frontline Chemoimmunotherapy in Chronic Lymphocytic Leukemia: Less Is More
ASCO Annual Meeting 2019 - Chicago, IL - 6/4/2019
Ibrutinib Treatment Reduces Myeloid Derived Suppressor Cell Numbers and Function in Chronic Lymphocytic Leukemia
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Extended Survival in CLL Patients Who Discontinued Idelalisib Because of Colitis Correlates with Higher Th17 Levels in Blood and Colon Tissue
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Musashi 2 Is Overexpressed in Poor Outcome CLL Patients and Their Proliferative Fraction and Silencing This Gene Induces Apoptosis and Increases Cell Adhesion and Move...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Chronic Lymphocytic Leukemia Treatment Patterns, Dosing, and Sequencing in the Era of Novel Targeted Therapies: Interim Analysis Results from the Prospective informCLL...
2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
Making Strides in the Treatment of B-Cell Malignancies: Keeping Up With New Data and Practice Recommendations
60th American Society of Hematology Annual Meeting - 11/30/2018
Join now to see all

Press Mentions

Managing Chronic Lymphocytic Leukemia in 2020: An Update on Recent Clinical Advances with a Focus on BTK and BCL-2 InhibitorsFebruary 26th, 2021
Study of Ibrutinib in CLL Shows a Benefit, but Raises Crucial QuestionsOctober 2nd, 2019
Barrientos Highlights Emerging Novel Therapies in the CLL PipelineMay 10th, 2019
Join now to see all